Druckenmiller Q1 2026 Watchlist: After a $914M ETF Blitz, What Could Duquesne Do Next?

Stanley Druckenmiller's latest visible filing is exactly the kind of portfolio that should not be reduced to a top-holdings list. Duquesne Family Office used Q4 2025 to bolt a large macro sleeve onto an existing healthcare-heavy core, building major positions in XLF, EWZ, and RSP while keeping Natera as the top holding. With the next 13F due on May 15, 2026, the practical question is whether Druckenmiller keeps pressing that broadening macro view or rotates again.

TL;DR

• Hook: Q4 introduced roughly $914.0M of macro and ETF deployment across XLF, EWZ, RSP, and index options.
• Core still visible: NTRA stayed the largest position at 12.80% while healthcare exposure remained meaningful.
• New macro sleeve: XLF rose to 6.70%, EWZ 5.50%, and RSP 5.00%.
• Selective tech, not blanket tech: AMZN and GOOGL were built while earlier healthcare weights such as TEVA and INSM shrank.
• Q1 watch: does Druckenmiller keep the macro overlay, or was Q4 a one-quarter breadth and financials trade?

Why This Filing Matters

Druckenmiller's public portfolio is useful when it gets directional. Q4 2025 did exactly that. The filing no longer looked like a pure healthcare or opportunistic stock-picking book. It started to read as a two-layer portfolio: existing healthcare conviction plus a macro overlay built for breadth, financials and emerging-market sensitivity.

What Q4 2025 Set Up

The new top-ten lineup says a lot on its own. Natera remained #1, but XLF, EWZ, and RSP immediately climbed into the upper tier. At the same time, Amazon and Alphabet became more important while names such as TEVA and Insmed lost visible weight. That is exactly the kind of transition that makes the next filing worth following in real time.

Visible Signals In Duquesne's Latest Filing

Position	Value	Weight	Why it matters
NTRA	$575.3M	12.80%	Healthcare remains the anchor despite the new macro sleeve.
XLF	$301.0M	6.70%	The clearest evidence that Druckenmiller wanted financial exposure in size.
EWZ	$247.2M	5.50%	A major Brazil and EM expression layered on top of the stock book.
RSP	$224.9M	5.00%	An explicit market-breadth and anti-concentration trade.
AMZN	$193.4M	4.30%	Selective tech participation rather than a wholesale exit from the theme.

Questions For Q1 2026

Does the breadth trade stay on?

If RSP and the financials sleeve remain large, the Q4 build will look like a durable view on broader participation beyond the most crowded mega-caps.

Was Brazil tactical or conviction-driven?

The EWZ position was large enough to matter immediately. If it survives or grows in Q1, readers should assume Druckenmiller still likes the EM and commodities-linked setup.

How much healthcare conviction remains under the macro layer?

Because NTRA stayed on top while TEVA and INSM were reduced, Q1 can reveal whether the sector is still the portfolio anchor or just legacy ballast.

Why does this filing matter more than a generic manager recap?

Because Druckenmiller's Q4 book clearly changed shape. The next filing can confirm whether that shape change was a thesis or just a trade.

Bottom Line

Duquesne's next filing should be watched as a portfolio-shape question, not a one-stock question. If the May 15 filing keeps XLF, EWZ, and RSP large while healthcare stays intact, Druckenmiller's Q4 macro overlay will look deliberate. If those sleeves shrink quickly, readers should treat Q4 as a tactical burst rather than a lasting stance.

Q&A

When is Duquesne's Q1 2026 13F due?

The next filing is due on May 15, 2026.

What was the biggest visible change in Q4 2025?

The addition of large XLF, EWZ and RSP positions changed the portfolio's structure.

Is Duquesne still concentrated in healthcare?

Yes, but less exclusively than before because the new macro sleeve became meaningful in size.